Sunday, January 23, 2022 2:15:04 PM
As a biologist, able to sufficiently understand the cellular biology and chemistry of the Anavex molecules, I’ve been following the progression of the company’s drug development for longer than six years. In that period, using only discretionary funds in my family budget, I’ve accumulated several thousand shares of AVXL. In 2023 I expect them to be worth quite a bit.
Of course, the AVXL share price ascent will rest on the clinical successes in the three ongoing drug trials, first (soon) with Rett syndrome, then with Parkinson’s disease dementia, and finally the big, game-changing Alzheimer’s study. The incessant quibbling here of poor management, unmet data release “deadlines,” etc. will finally evaporate.
And, yes, in 2023 there will be another new message board topic: What other diseases can blarcamesine now be used to treat? By then, the drug’s mechanism of action (MOA) will be no longer in question. Blarcamesine, as a unique sigma-1 receptor ligand activates that protein, causing it to propitiously facilitate a diversity of favorable cell processes. Those processes suppress or minimize the symptoms of Rett syndrome, Parkinson’s disease, and Alzheimer’s. Three otherwise recalcitrant central nervous system diseases without useful treatments. Others, not just biologists, will then be asking, “If this drug works so well and so safely against these three CNS diseases, why won’t it work on others?”
Whereupon, for me, enters the GABA/glutamate optimization in girls with Rett syndrome. The Phase I safety and tolerability trials on a few girls with Rett showed that the drug was safe, and it also favorably increased GABA concentrations and reduced glutamate levels. There is no reason to believe that those results won’t continue into the ongoing trial; validating the Phase I results.
For me, it’s the GABA question. I have a rare CNS disease, hereditary spastic paraplegia (HSP). In the long motor neurons controlling the adductor and other muscles in my legs, GABA, gamma-aminobutyric acid, is deficient. I can walk, but only with a walker; can no longer ascend staircases. HSP has caused a neurogenic bladder condition; now have a suprapubic catheter.
GABA is a helpful inhibitor of extraneous nerve impulses. It effectively blocks “nerve static” signals, calming and smoothing nerve impulses. With normalized levels of GABA, muscles are properly controlled and signaled by nerves. When GABA is deficient (as in the case of Rett syndrome) all sorts of nerve impulse problems occur: “Rett syndrome, a serious neurodevelopmental disorder, has been associated with an altered expression of different synaptic-related proteins and aberrant glutamatergic and ?-aminobutyric acid (GABA)ergic neurotransmission.”
https://pubmed.ncbi.nlm.nih.gov/31947619/
SO, when blarcamesine is authorized for Rett syndrome, my neurologist, if his institution will allow it, will prescribe blarcamesine for my HSP, off label. It will be very expensive. But I’ll liquidate a portion of my AVXL position to underwrite my personal experiment with blarcamesine. Of course, the rest of the HSP community will spot the GABA factor, too; will petition to gain FDA approval for HSP outright, or seek a prompt clinical trial.
HSP will be a new CNS disease to be treated with blarcamesine. Another similar disease, primary lateral sclerosis, PLS, will be another one.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM